Antitrust issues are complex by nature, combining the threat of regulatory scrutiny and potential criminal prosecution with private civil litigation. They can involve multiple governmental agencies in the U.S. and abroad, as well as numerous private parties. Our team defuses antitrust threats with a combination of litigation brilliance, the strong business acumen of seasoned commercial litigators and the credibility possessed by, among others, former top U.S. Federal Trade Commission and U.S. Department of Justice regulators.
Paul, Weiss secured a significant antitrust appellate victory for global medical technology company Becton Dickinson & Company (BD). The landmark decision, by the U.S. Court of Appeals for the Fifth Circuit, reversed and vacated a $340 million verdict in favor of a competitor, Retractable Technologies, Inc. (RTI).
In September 2013, Paul, Weiss tried to a jury in the Eastern District of Texas 12 antitrust claims asserted by RTI, and won all but one claim, attempted monopolization by means of false advertising and patent infringement. In the first appellate decision in recent years to squarely address whether patent infringement and false advertising can constitute anticompetitive conduct under antitrust laws, the Fifth Circuit ruled that the claim against BD was "infirm as a matter of law" and rendered judgment for BD.
Writing for the panel, U.S. Circuit Judge Edith H. Jones wrote that false advertising and patent infringement cannot be considered anticompetitive conduct. While it might harm a competitor, the panel concluded, it does not harm the competitive process.POSTED ON December 2, 2016 » Learn More About This Practice